The close interplay of clinicians, tumor biologists, and synthetic chemists has led to promising outcomes in the field of CRPC research over the last years, and interdisciplinary work will continue to help HDAC inhibitor-based therapy to play a prominent role as efficient and well-tolerated CRPC treatment in the future. The gene discussed is HDAC9; the disease is neoplasm.